Janus
Kinase Inhibitor Market, by Drugs (Baricitinib, Tofacitinib, Ruxolitinib,
and Pipeline Drugs (Peficitinib)), by Indication (Rheumatoid Arthritis,
Psoriatic Arthritis, Systemic Lupus Erythematosus, and Others), by Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026
Janus kinase (Jak) is a family of
non-tyrosine receptor kinases, which play a major role in cytokine signaling.
Binding of cytokines (ligand) to receptor results in receptor dimerization and
ultimately activates Jak-mediated phosphorylation of the receptor. Jak
phosphorylates STAT (Signal Transducer and Activator of Transcription proteins)
and STAT dimer carries out the transcription of genes which are critical for
signal cascade involved in inflammatory and immune response. Therefore, Janus
kinase is used as a target in treatment of autoimmune disorders such as
rheumatoid arthritis.
Janus Kinase Inhibitor Market
Drivers
Jak inhibitors are increasingly
preferred for industrial research due to their critical role in immune response
signaling. For instance, in June 2018, Eli Lilly and Company announced approval
from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib) —
an oral medication for rheumatoid arthritis in adults. Approval was granted for
use of baricitinib in combination with methotrexate (MTX) or other
disease-modifying antirheumatic drugs (DMARDs) or as monotherapy. The drug
inhibits activation of Jak1/2 (Janus kinase 1 and 2) and decreases the
production of inflammatory cytokines, thereby inhibiting inflammatory response.
Therefore, increasing launch of new drugs is expected to fuel the global janus
kinase inhibitor market growth over the forecast period.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2553
Psoriatic arthritis is a form of
arthritis, which is characterized by red patches of skin with silvery scales.
Tofacitinib is a janus kinase inhibitor, which modulates cytokines that are
required for signaling of inflammatory and immune response. Inclusion of new
treatment options is expected to boost the global janus kinase inhibitor market
growth over the forecast period. For instance, in December 2017, Pfizer Inc.
received approval from the U.S. FDA for XELJANZ (TOFACITINIB) for treatment of
adult patients suffering from psoriatic arthritis (PsA).
Furthermore, key manufacturers
and research organizations are focused in research and development of new janus
kinase inhibitor drugs. For instance, M.D. Anderson Cancer Center, in
collaboration with Incyte Corporation, conducted phase -2 clinical trials
(study completed in March 2017) to check effect of ruxolitinib in controlling
advanced hematological malignancies.
Ruxolitinib is an inhibitor of Jak 1 and Jak2 kinases and arrests growth
of transformed cells. Therefore, active research and development of new janus
kinase inhibitor drugs is expected to fuel the global janus kinase inhibitor
market growth over the forecast period.
Janus Kinase Inhibitor Market
Regional Analysis
The Janus kinase pathway mediates
intracellular signaling of over sixty cytokines. Dysregulation of cytokines
causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic
disease, which is characterized by inflammation of connective tissues such as
cartilage and blood vessel lining. According to National Center for
Biotechnology Information (NCBI), the highest prevalence and incidence of SLE
was in recorded in North America (23.2/100 000 person) during the period August
2013- September 2016. Therefore, high prevalence of SLE is expected to boost
North America janus kinase inhibitor market growth over the forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/janus-kinase-inhibitor-market-2553
Increasing research and
development projects for launch of new drugs is expected to fuel Asia Pacific
janus kinase inhibitor market growth over the forecast period. For instance,
Astellas Pharma Inc. — a Japan-based pharmaceutical company — conducted Phase-3
clinical trial (study completed in November 2017) of drug Peficitinib for
treatment of Rheumatoid arthritis. The study was conducted to check the
superiority of Peficitinib alone and in combination with disease-modifying
antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis who did not
show sufficient response to DMARDs. Peficitinib is an inhibitor of Jak 1 and
Jak that inhibits Interleukin 2 dependent T cell proliferation and STAT5
phosphorylation. These factors are expected to support global janus kinase
inhibitor market growth over the forecast period.
Janus Kinase Inhibitor Market
Restraints
Regulatory challenges in launch
of Janus kinase inhibitors is expected to hinder the market growth. For
instance, in April 2017 the U.S. FDA requested Eli Lilly & Company to
provide additional clinical data for the dosing of drug Olumiant to
characterize safety concerns. Later in April 2018, the FDA denied company the
approval for 4mg once daily dose of Olumiant due to safety concerns regarding
arterial and venous thrombosis.
Janus Kinase Inhibitor Market Key
Players
Some of the key players operating
in the global Janus kinase inhibitor market include, Eli Lilly and Company,
Astellas Pharma Inc., Pfizer Inc.,
Baxter International Inc., Novartis International AG, Gilead Sciences
Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte Corporation.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2553
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment